This Phase 2 study is a 2-arm, multi-center, double-masked, placebo-controlled, 2:1 randomized sequential trial design in new onset T1D participants (within 100 days of diagnosis). THIS STUDY IS ENROLLING BY INVITATION ONLY 

The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.THIS STUDY IS ENROLLING BY INVITATION ONLY

EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy THIS STUDY IS ENROLLING BY INVITATION ONLY - This is an open-label, treatment extension study to evaluate the safety, tolerability, and durability of effect in long-term dosing of sevasemten. EDG-5506-203 MESA will provide continued access to sevasemten treatment to participants with Becker muscular dystrophy who were previously enrolled in EDG-5506-002 ARCH, completed EDG-5506-201 CANYON and GRAND CANYON, or completed EDG-5506-202 DUNE.

The purpose of this study in children with Noonan syndrome is to evaluate the effect of 3 doses of vosoritide on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants who are ≥ 3 years old, and

The purpose of the study is to determine the feasibility postoperative vagal nerve stimulation and measure the effect on the plasma inflammatory markers on postoperative days 1-3.THIS STUDY IS ENROLLING BY INVITATION ONLY - Recruitment and eligibility screening will occur through standard clinical pathways within the Department of Neurosurgery. Spine surgeons caring for patients scheduled for elective thoraco-lumbar spine surgery will preliminarily identify individuals who may meet basic eligibility criteria based on the surgical schedule and medical record. Surgeons or designated clinical staff will notify the research team of potentially eligible patients, after which trained study personnel will conduct a standardized screening using predefined inclusion and exclusion criteria to confirm eligibility. Eligible patients will be approached by the research team in the preoperative clinic or, when appropriate, during the inpatient preoperative period. No recruitment will occur through public advertisements, and patients will not be contacted outside of established clinical encounters.

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Youth with type 1 or type 2 diabetes mellitus (T1D; T2D) from low socioeconomic backgrounds in rural western Kenya and in urban or rural Indiana struggle with poor glycemic control and have limited access to peer-support and ongoing diabetes education. The impact of peer-support and education groups that address social, cultural, and emotional needs on diabetes self-management has yet to be evaluated in this population. The objective of this work is to co-develop a diabetes education curriculum which can eventually be peer-led by youth with T1D or T2D in rural western Kenya and in Indiana to strengthen diabetes self-management and glycemic control.THIS STUDY IS ENROLLING BY INVITATION ONLY - Eligible patients will be recruited in one of the following ways: health care providers will identify eligible adolescents/young adults during diabetes clinic visits, a letter will be mailed to patients who have been seen for diabetes in one of the clinics within the last 12 months, or a member of the research team will call eligible patients.